Clinical Trial

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-04-11; most recent amendment 2026-06-09.
Trial Details
NCT Number NCT06934889
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Glioblastoma, Gliosarcoma
Enrollment 60 participants
Start Date 2025-04-07
Primary Completion 2028-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-10